TNFSF13B and systemic lupus erythematosus: Recent advancements in targeting the BAFF/APRIL system have yielded clinically approved therapies: belimumab (BAFF inhibitor) and telitacicept (TACI-Fc fusion protein) for SLE, offering novel therapeutic avenues.